StudyFinder
A Phase I Study of HCW9218, a Bifunctional TGF-B; Antagonist/IL-15 Protein Complex, in Select Advanced Solid Tumors After Failing at Least Two Prior Therapies
Recruiting
This is an early study of a new drug, HCW9218, to treat certain solid tumors (except pancreatic cancer and brain tumors) that have not responded to usual treatment. People must have received at least two other types of treatment for the cancer. We are testing different doses of the drug to find the maximum dose that is tolerated.
All
18 Years to old
Inclusion Criteria:
Histologically or cytologically confirmed advanced/metastatic solid tumor cancer (except pancreatic and primary brain cancers), has failed at least 2 prior lines of therapy given either in the recurrent or metastatic setting and must be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.
Measurable disease per RECIST v 1.1.
Acute effects of any prior therapy must have resolved to baseline or Grade ≤1 NCI CTCAE v5 except for AEs not constituting a safety risk by enrolling Investigator judgment.
Age 18 years or older at the time of consent.
ECOG Performance Status 0 or 1.
Evidence of adequate organ function within 14 days prior to enrollment as defined in Section 4.1.6.
Adequate pulmonary function with PFTs >50% FEV1 if symptomatic or known impairment.
Sexually active persons of child-bearing potential or with partners of childbearing potential must agree to use a highly effective form of contraception (refer to Section 4.1.10 for acceptable methods) for at least 28 days after the last dose of HCW9218.
Provides voluntary written consent prior to the performance of any research related activity.
Exclusion Criteria:
Pregnant or breastfeeding.
History of clinically significant vascular disease, including any of the following within 6 months prior to start of study treatment: MI or unstable angina, percutaneous coronary intervention, bypass grafting, ventricular arrhythmia requiring medication, stroke or transient ischemic attack, symptomatic peripheral arterial disease.
Marked baseline prolongation of QT/QTc interval (e.g., demonstration of a QTc interval greater or equal to 470 milliseconds by Fridericia's correction).
Known or suspected untreated CNS metastases.
Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment start.
Other prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the subject is currently in complete remission, or any other cancer from which the subject has been disease-free for 3 years after surgical treatment.
Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.
Prior therapy with TGF-β antagonist, IL-15 or analogs.
Concurrent use of St. John's wort and and/or other herbal CYP modulators within 7 days of Day 1. Must agree to not use during study treatment through the end of treatment visit to be eligible.
Known autoimmune disease requiring active treatment. Persons with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
Prior organ allograft or allogeneic transplantation.
Known HIV-positive or AIDS.
Psychiatric illness/social situations that would limit compliance with study requirements.
Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this studyDrug: HCW9218
Solid Tumor
Phase I Clinic, Clinics and Surgery Center (CSC)
Melissa Geller - gelle005@umn.edu
Melissa Geller, MD
Phase 1
STUDY00015102
STUDY00015102
See this study on ClinicalTrials.gov